Effects of Rosiglitazone on Muscle Gene Expression and Insulin Sensitivity in HIV Patients
Author Information
Author(s): Dennis C. Mynarcik, Margaret A. McNurlan, Mark M. Melendez, James A. Vosswinkel, Marie C. Gelato
Primary Institution: Stony Brook University Medical Center
Hypothesis
Does rosiglitazone treatment improve insulin sensitivity by altering muscle gene expression in individuals with HIV-associated insulin resistance?
Conclusion
Rosiglitazone treatment significantly improved insulin sensitivity in HIV-infected individuals with insulin resistance, correlating with changes in muscle gene expression.
Supporting Evidence
- Rosiglitazone improved insulin sensitivity in HIV-infected individuals with insulin resistance.
- Changes in muscle gene expression were correlated with improvements in insulin sensitivity.
- Insulin sensitivity was significantly lower in the HIV-IR group compared to controls.
Takeaway
This study found that a medicine called rosiglitazone can help people with HIV who have trouble using insulin, by changing how their muscles work.
Methodology
The study assessed muscle gene expression using real-time PCR and measured insulin sensitivity through hyperinsulinemic-euglycemic clamps before and after 12 weeks of rosiglitazone treatment.
Potential Biases
Potential bias due to the small number of participants and the specific population studied.
Limitations
The study had a small sample size and may not be generalizable to all HIV-infected individuals.
Participant Demographics
Participants included 22 seronegative controls, 21 HIV-infected individuals with normal insulin sensitivity, and 19 HIV-infected individuals with insulin resistance.
Statistical Information
P-Value
P < .001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website